Accord Logo

Intended for UK patients and members of the public

Apixaban Film-coated Tablets

Active Ingredients

Product Documentation

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.

Report a side effect or a product complaint

Apixaban Accord 2.5mg film-coated tablets

PL Number:
PLGB 20075/1405
MA Holder:
Accord Healthcare Limited
Product Classification:
POM
Product Status:
Active

Product Documentation

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.

Report a side effect or a product complaint

Apixaban Accord 5mg Film-coated Tablets

PL Number:
PLGB 20075/1406
MA Holder:
Accord Healthcare Limited
Product Classification:
POM
Product Status:
Active

Product Documentation

  • Description of update: To update sections 4.2 and 5.1 of the SmPC in-line with reference product (Eliquis 2.5 mg/5 mg film coated tablets; procedure number with outcome: EMEA/H/C/002148/II/0088; MAH: Bristol Myers Squibb/Pfizer EEIG, Ireland). Additionally, to update SmPC section 4.2, 4.3, 4.4, 4.6, 4.7, 4.8, 5.1, 5.2 and PIL section 1, 2, 3 and 4 with editorial changes in line with reference product and corrected typo errors in SmPC section 5.1, 5.2 and PIL section 2, 4.

    PIL sections updated: 1, 2, 3, 4 and 6.

  • Description of update: To update sections 4.2 and 5.1 of the SmPC in-line with reference product (Eliquis 2.5 mg/5 mg film coated tablets; procedure number with outcome: EMEA/H/C/002148/II/0088; MAH: Bristol Myers Squibb/Pfizer EEIG, Ireland). Additionally, to update SmPC section 4.2, 4.3, 4.4, 4.6, 4.7, 4.8, 5.1, 5.2 and PIL section 1, 2, 3 and 4 with editorial changes in line with reference product and corrected typo errors in SmPC section 5.1, 5.2 and PIL section 2, 4.

    SmPC sections updated: 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.1, 5.2 and 10.

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.

Report a side effect or a product complaint

General FAQs

For any further assistance, please get in touch.

View product information as a: